SCHEMBL6545599

SCHEMBL6545599

C=CCOP(=O)(OCC=C)c1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CA2 P00918 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP14 P50281 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MMP1 P03956 2/20 0.35
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPK14 Q16539 1/20 0.33
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735754 0.78 PKM (0.35) CA2CA9SMN1; SMN2TSHRCYP3A4
SCHEMBL6545061 0.76 MAPT (0.49) CA2CA9MEN1KMT2ASMN1; SMN2
SCHEMBL3548978 0.74 HPGD (0.49) MAOAMAOBCA2CA9MEN1
SCHEMBL331731 0.74 PKM (0.49) CA2MEN1KMT2ASMN1; SMN2GAA
Vinyl Chloride SCHEMBL11613404 0.73 PKM (0.45) CA2CA9MEN1KMT2ASMN1; SMN2
SCHEMBL6545932 0.73 LMNA (0.43) CA2CA9MEN1KMT2AHPGD
SCHEMBL6545602 0.71 CA2 (0.39) MAOAMAOBCA2MMP2MMP9
SCHEMBL6545924 0.71 GAA (0.43) CA2MMP2MMP8MMP14CA9
SCHEMBL5676701 0.70 MAOA (0.50) MAOAMAOBCA2MMP2MMP9
SCHEMBL2735765 0.69 RAB9A (0.34) CA2CA9SMN1; SMN2GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379533-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS Leo Pharma A/S (DK) 2004-01-14 EP disclosed
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed
WO-2002083696-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS LEO PHARMA A/S (DK) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 MAOA 381/4885MAOB 784/4885CA2 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.